Literature DB >> 21921726

Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.

Gretchen S Stuart, Agnes Moses, Amanda Corbett, Grace Phiri, Wiza Kumwenda, Nkhafwire Mkandawire, Joseph Chintedze, Gabriel Malunga, Mina Hosseinipour, Myron S Cohen, Frank Z Stanczyk, Angela D M Kashuba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21921726      PMCID： PMC3176587          DOI： 10.1097/QAI.0b013e31822b8bf8

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  12 in total

1.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.

Authors:  F Z Stanczyk; M Hiroi; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Contraception       Date:  1975-09       Impact factor: 3.375

2.  Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

Authors:  Naser L Rezk; Richard R Tidwell; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

3.  Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

Authors:  David W Haas; John A Bartlett; Janet W Andersen; Ian Sanne; Grant R Wilkinson; John Hinkle; Franck Rousseau; Christiana D Ingram; Audrey Shaw; Michael M Lederman; Richard B Kim
Journal:  Clin Infect Dis       Date:  2006-08-15       Impact factor: 9.079

4.  Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins.

Authors:  Joseph W Goldzieher; Frank Z Stanczyk
Journal:  Contraception       Date:  2008-06-02       Impact factor: 3.375

5.  The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.

Authors:  Heather Sevinsky; Timothy Eley; Anna Persson; Dennis Garner; Cynthia Yones; Richard Nettles; Kathryn Krantz; Richard Bertz; Jenny Zhang
Journal:  Antivir Ther       Date:  2011

6.  Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.

Authors:  Mina C Hosseinipour; Amanda H Corbett; Cecelia Kanyama; Idah Mshali; Severiano Phakati; Nazer L Rezk; Charles van der Horst; Angela D M Kashuba
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

7.  Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial.

Authors:  D A Grimes; A J Godwin; A Rubin; J A Smith; M Lacarra
Journal:  Obstet Gynecol       Date:  1994-01       Impact factor: 7.661

8.  Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.

Authors:  Donna Mildvan; Robert Yarrish; Ann Marshak; Herbert W Hutman; Marita McDonough; Michael Lamson; Patrick Robinson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

9.  Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.

Authors:  T M Price; R E Dupuis; B R Carr; F Z Stanczyk; R A Lobo; W Droegemueller
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

Review 10.  Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.

Authors:  Shareen Y El-Ibiary; Jennifer M Cocohoba
Journal:  Eur J Contracept Reprod Health Care       Date:  2008-06       Impact factor: 1.848
View more
  14 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

2.  Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.

Authors:  Teresa Barcellos; Melissa Natavio; Frank Z Stanczyk; Dandan Luo; William J Jusko; Nicole M Bender
Journal:  Contraception       Date:  2019-06-10       Impact factor: 3.375

Review 3.  Contraception for HIV-Infected Adolescents.

Authors:  Athena P Kourtis; Ayesha Mirza
Journal:  Pediatrics       Date:  2016-09       Impact factor: 7.124

4.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 5.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 6.  Current and future contraceptive options for women living with HIV.

Authors:  Rena C Patel; Elizabeth A Bukusi; Jared M Baeten
Journal:  Expert Opin Pharmacother       Date:  2017-09-19       Impact factor: 3.889

7.  Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Authors:  Maria Pyra; Renee Heffron; Nelly R Mugo; Kavita Nanda; Katherine K Thomas; Connie Celum; Athena P Kourtis; Edwin Were; Helen Rees; Elizabeth Bukusi; Jared M Baeten
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

8.  The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Authors:  M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

9.  Interactions between Hormonal Contraception and Anti-Retroviral Therapy: An Updated Review.

Authors:  Gopika R Krishna; Lisa B Haddad
Journal:  Curr Obstet Gynecol Rep       Date:  2020-05-31

10.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.